Regenerative technology for future therapy of erectile dysfunction.

摘要: Although oral phosphodiesterase-5 (PDE5) inhibitors are generally an effective and well-tolerated therapy for erectile dysfunction (ED), such therapies still far from curing ED do not reverse the vasculopathic or neuropathic processes associated with ED. Moreover, certain populations organic ED, as that resulting diabetes radical prostatectomy (RP), respond poorly to PDE5 inhibitors. This reduced responsiveness may be related severity of endothelial nerve damage. Because effects rely on endogenous nitric oxide (NO) formation, if bioavailable NO is insufficient result severe damage, fail increase level cGMP above necessary threshold.